AI Article Synopsis
- - The study focused on understanding the prevalence of gastrointestinal and behavioral symptoms related to methotrexate (MTX) use in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients, identifying this condition as MTX intolerance.
- - Researchers used the Methotrexate Intolerance Severity Score (MISS) to assess symptoms in 291 patients, finding that 42.3% experienced gastrointestinal issues, with 11% classified as having MTX intolerance, especially higher in those receiving parenteral MTX.
- - The findings highlight that patients not only suffer from gastrointestinal symptoms after taking MTX but also experience them beforehand, underscoring the importance of monitoring with the MISS to manage MTX intolerance effectively and
Article Abstract
Introduction: The aim of this study was to determine the prevalence of gastrointestinal and behavioural symptoms occurring before (anticipatory/associative) and after methotrexate (MTX) administration, termed MTX intolerance, in rheumatoid (RA) and psoriatic arthritis (PsA).
Methods: Methotrexate Intolerance Severity Score (MISS), previously validated in juvenile idiopathic arthritis patients, was used to determine MTX intolerance prevalence in 291 RA/PsA patients. The MISS consisted of four domains: abdominal pain, nausea, vomiting and behavioural symptoms, occurring upon, prior to (anticipatory) and when thinking of MTX (associative). MTX intolerance was defined as ≥6 on the MISS with ≥1 point on anticipatory and/or associative and/or behavioural items.
Results: A total of 123 patients (42.3%) experienced at least one gastrointestinal adverse effect. The prevalence of MTX intolerance was 11%. MTX intolerance prevalence was higher in patients on parenteral (20.6%) than on oral MTX (6.2%) (p < 0.001).
Conclusion: Besides well-known gastrointestinal symptoms after MTX, RA and PsA patients experienced these symptoms also before MTX intake. RA and PsA patients on MTX should be closely monitored with the MISS for early detection of MTX intolerance, in order to intervene timely and avoid discontinuation of an effective treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978699 | PMC |
| http://dx.doi.org/10.1186/ar4413 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!